We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Lixte Biotechnology Holdings Inc (LIXT) USD0.0001

Sell:$0.73 Buy:$0.79 Change: $0.00895 (1.20%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Change: $0.00895 (1.20%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Change: $0.00895 (1.20%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Lixte Biotechnology Holdings, Inc. is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs compounds to attack those targets. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and encompasses two categories of compounds at various stages of pre-clinical and clinical development that has the therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. The Company has developed two series of pharmacologically active drugs, the LB-100 series and the LB-200 series. The LB-100 series consists of structures, which is treated not only several types of cancer but also vascular and metabolic diseases. The LB-200 series contains compounds, which are useful for the treatment of chronic hereditary diseases.

Contact details

No. 2, 248 Route 25A
United States
+1 (310) 2032902

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$12.18 million
Shares in issue:
16.65 million
United States
US dollar

Key personnel

  • John Kovach
    Chairman of the Board, President, Chief Executive Officer, Chief Scientific Officer
  • Robert Weingarten
    Chief Financial Officer, Vice President
  • Eric Forman
    Chief Administrative Officer
  • James Miser
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.